Literature DB >> 15042671

X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth.

Yuan-Jia Chen1, Alexander Vortmeyer, Zhengping Zhuang, Fathia Gibril, Robert T Jensen.   

Abstract

BACKGROUND: Recent studies have shown that tumor growth, rather than hormone overproduction, is the leading cause of death among patients with gastrinomas and other malignant gastrointestinal endocrine tumors. No patient/laboratory characteristics accurately predict which tumors will exhibit aggressive growth. Furthermore, little is known regarding the molecular pathogenesis of these tumors. X-chromosome loss of heterozygosity (LOH) occurs in some nonendocrine tumors, and its presence can be associated with aggressive growth/decreased survival. Data on X-chromosome LOH in gastrointestinal endocrine tumors are conflicting. Therefore, the purpose of the current study was to determine whether X-chromosome LOH occurred in gastrinomas and, if so, whether it was correlated with tumor growth, tumor behavior, and/or prognosis.
METHODS: X chromosome allelotyping was performed using 12 microsatellite markers spaced throughout the chromosome using DNA from leukocytes and microdissected gastrinoma specimens from 16 female patients. The presence of X-chromosome LOH was analyzed for correlations with clinical and laboratory tumor characteristics as well as tumor growth characteristics.
RESULTS: Nine gastrinoma specimens (56%) had X-chromosome LOH, ranging from 6% to 23% at the 12 different loci studied. X-chromosome LOH was significantly associated with aggressive postoperative tumor growth, increased primary tumor size, and pancreatic primaries. In 6 tumor specimens, LOH occurred on Xp22.1-22.3 over a 28.4-centimorgan region.
CONCLUSIONS: X-chromosome LOH was common in gastrinoma specimens from female patients, and its presence was found to be a potentially useful molecular/genetic prognostic factor for aggressive growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042671     DOI: 10.1002/cncr.20104

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Fathia Gibril; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2005-05

2.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

Review 3.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

Review 4.  Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors.

Authors:  Susanne van Eeden; G Johan A Offerhaus
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

Review 5.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 6.  Prognostic factors in gastrointestinal endocrine tumors.

Authors:  Guido Rindi; Tiziana D'Adda; Elisabetta Froio; Giovanni Fellegara; Cesare Bordi
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

7.  Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient.

Authors:  Jacklyn Wy Yong; Meng Ling Choong; SiFang Wang; Yu Wang; Shermaine Qy Lim; May Ann Lee
Journal:  Cancer Cell Int       Date:  2014-09-20       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.